article thumbnail

Insurance Coverage for Psychedelic Therapy

Bill of Health

By Vincent Joralemon As therapies using drugs like MDMA, psilocybin, and LSD advance through the FDA research and approval pipeline, patients should be prepared for steep price tags attached to these procedures. This is typical—without a seal of approval from FDA, insurers are reluctant to pay for off-label treatments.

FDA 201
article thumbnail

Psychedelics Are Cheap. Psychedelic Treatment Is Not.

Bill of Health

The FDA approved S-ketamine to treat depression in 2019. Still, to me, the most promising route to access is probably through FDA approval (which means more clinical trials) and expanded insurance coverage. Yet, insurance coverage alone is an imperfect solution because millions of Americans have no health insurance.

FDA 261
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Humana Becomes First Insurer to Cover TMS Therapy for Adolescent Depression

HIT Consultant

– Humana, a health insurance provider, has become the first commercial payer to update its policy in response to the FDA’s recent clearance of NeuroStar TMS for adolescents aged 15-21 with MDD. Food and Drug Administration (FDA) granted clearance for NeuroStar TMS as a first-line add-on treatment for adolescent MDD.

FDA 87
article thumbnail

How Will New FDA Hearing Aid Regulations Impact Health Plans?

HIT Consultant

First, let’s examine the new regulatory framework the FDA established. The regulations may provide an opportunity for health insurers to attract new members – and retain existing ones – with hearing loss. Health plans should be on the alert for potential pitfalls arising from the new regulations. million U.S.

FDA 98
article thumbnail

The Self-Prescribing Consumer: DIY Comes to Prescriptions via GLP-1s, the OPill, and Dexcom’s CGM

Health Populi

A screenshot of part of this evaluation is shown here, describing seven sites by cost to the consumer, process of evaluating-prescribing-ordering, and whether health insurance would cover the consumers’ cost of the medicine (generally, “no”). Stay tuned!

FDA 77
article thumbnail

First COVID-19 Breathalyzer Test Authorized By FDA

The Health Law Firm Blog

Board Certified by The Florida Bar in Health Law On April 14, 2022, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization for the first Covid-19 diagnostic test that uses breath samples. By George F. Indest III, J.D., The test, made by Texas-based company, InspectIR Systems, is authorized for those [.]

article thumbnail

EU and US Regulatory Challenges Facing AI Health Care Innovator Firms

Bill of Health

The main federal health privacy law, the Health Insurance Portability and Accountability Act of 1996 (HIPAA) applies only to “covered entities” like health insurers, claims- processing clearinghouses, and health care providers and their business associates, and only to a subset of protected health care information.

FDA 282